A Study to Assess Bioequivalence of a New Tapentadol Extended-Release Tablet With Respect to a Tapentadol Extended Release Tablet Under Fasted Conditions in Healthy Subjects

NCT02019485 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Tapentadol Extended Release (ER) Tamper-Resistant Formulation (TRF)
DRUG: Tapentadol Prolonged-Release Formulation 2 (PR2)

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.